Global Apremilast Market, By Strength (10mg, 20mg, 30mg), Drug Class (Antirheumatics, Others), Demographic (Adult, Pediatric), Application (Psoriasis, Psoriatic Arthritis, Others), Dosage Form (Tablet, Others), Route of Administration (Oral, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Market Analysis and Insights : Global Apremilast Market
Apremilast market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 5% in the above mentioned forecast period and is likely to reach the USD 3.41 billion by 2029.
Apremilast is a phosphodiesterase 4 (also called PDE4) inhibitor that aims in reducing the inflammation by suppressing the immune system. It is used to treat adults with active psoriatic arthritis. It's also used to treat moderate to severe plaque psoriasis adults who are already receiving phototherapy or other psoriasis treatments. Apremilast is also used to treat adult patients with Behçet's illness who have mouth ulcers (a disease causing inflammation in blood vessels). Apremilast is a twice-daily tablet to take. You gradually raise the dose over the first week to lessen the risk of side effects. Otezla is a brand name for this medication.
The rise in the prevalence of arthritis is the major factor driving the market’s growth rate. Additionally, rising healthcare expenditure is the market driver influencing growth rate of the apremilast market. Furthermore, increasing geriatric population and upsurge in the number of clinical trial studies are the factors that will expand the apremilast market. Other factors including rise in the growing government initiatives and rising awareness will positively impact the market growth rate. Another significant factor that will cushion the growth of apremilast market is the increase in demand from various end-use industries. Also, a rise in disposable income and rapid urbanization will escalate the market growth rate for the mentioned forecast period mentioned above.
Moreover, the rise in the research and development activities and emerging new markets will provide beneficial opportunities for the apremilast market in the forecast period of 2022-2029.
However, the high cost associated with product and side effects such as nausea, diarrhea, vomiting, stomach pain, dizziness, loss of appetite, sore throat, and others will hamper the growth of the apremilast market. Lack of awareness will further challenge the apremilast market in the forecast period mentioned above.
This apremilast market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the apremilast market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Apremilast Market Scope and Market Size
The apremilast market is segmented on the basis of strength, drug class, demographic, application, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of strength, the apremilast market is segmented into 10mg, 20mg, and 30mg.
- On the basis of drug class, the apremilast market is segmented into antirheumatics, and others.
- On the basis of demographic, the apremilast market is segmented into adult, and pediatric.
- On the basis of application, the apremilast market is segmented into psoriasis, psoriatic arthritis, and others.
- On the basis of dosage form, the apremilast market is segmented into tablet and others.
- On the basis of route of administration, the apremilast market is segmented into oral and others.
- On the basis of end-users, the apremilast market is segmented into clinic, hospital and others.
- The apremilast market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Apremilast Market Country Level Analysis
Apremilast market is analyzed and market size information is provided by the country, strength, drug class, demographic, application, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the apremilast market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the apremilast market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022 to 2029 due to the increasing research and development activities and rising government support in this region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Apremilast market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Apremilast Market Share Analysis
Apremilast market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to apremilast market research.
Some of the major players operating in the apremilast market are Amneal Pharmaceuticals LLC., Amgen Inc., Bristol-Myers Squibb Company, Aurobindo Pharma, Lupin, APINO PHARMA CO., LTD., Senova Technology Co. Ltd., Tiefenbacher API + Ingredients GmbH & Co. KG, GlaxoSmithKline plc, Pfizer Inc., Eli Lilly and Company, AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Johnson & Johnson Private Limited, Takeda Pharmaceutical Company Limited., and UCB S.A., among others.
SKU-